176 related articles for article (PubMed ID: 32761317)
1. Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma.
Salah S; To YH; Khozouz O; Ismail T; Yaser S; Alnsour A; Shahin O; Sultan I; Abuhijlih R; Halalsheh H; Abuhijla F; Lewin J
Clin Transl Oncol; 2021 Apr; 23(4):757-763. PubMed ID: 32761317
[TBL] [Abstract][Full Text] [Related]
2. Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
Ju HY; Park M; Lee JA; Park HJ; Park SY; Kim JH; Kang HG; Yang HC; Park BK
Cancer Res Treat; 2022 Apr; 54(2):563-571. PubMed ID: 34126703
[TBL] [Abstract][Full Text] [Related]
3. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
Xu J; Xie L; Sun X; Liu K; Liang X; Cai Z; Tang X; Guo W
Clin Cancer Res; 2023 Mar; 29(6):1040-1046. PubMed ID: 36622702
[TBL] [Abstract][Full Text] [Related]
4. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.
Wang BC; Xiao BY; Lin GH
BMC Cancer; 2022 Mar; 22(1):349. PubMed ID: 35361149
[TBL] [Abstract][Full Text] [Related]
6. High Response Rates and Promising Outcomes of Patients with Relapsed Ewing Sarcoma, Especially in Adolescents and Young Adults Treated on a Novel Hybrid Salvage Chemotherapy Regimen.
Vijayasekharan K; Ramanathan S; Chinnaswamy G; Prasad M; Gulia A; Janu A; Rekhi B; Ramadwar M; Khanna N; Laskar S; Puranadare N; Bajpai J; Puri A; Banavali S; Vora T
J Adolesc Young Adult Oncol; 2021 Apr; 10(2):185-192. PubMed ID: 32706630
[No Abstract] [Full Text] [Related]
7. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.
Palmerini E; Jones RL; Setola E; Picci P; Marchesi E; Luksch R; Grignani G; Cesari M; Longhi A; Abate ME; Paioli A; Szucs Z; D'ambrosio L; Scotlandi K; Fagioli F; Asaftei S; Ferrari S
Acta Oncol; 2018 Jul; 57(7):958-964. PubMed ID: 29533113
[TBL] [Abstract][Full Text] [Related]
8. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
Chugh R; Ballman KV; Helman LJ; Patel S; Whelan JS; Widemann B; Lu Y; Hawkins DS; Mascarenhas L; Glod JW; Ji J; Zhang Y; Reinke D; Strauss SJ
Cancer; 2021 Apr; 127(8):1301-1310. PubMed ID: 33289920
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Metts JL; Trucco M; Weiser DA; Thompson P; Sandler E; Smith T; Crimella J; Sansil S; Thapa R; Fridley BL; Llosa N; Badgett T; Gorlick R; Reed D; Gill J
Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
Devadas SK; Banavali S
Gulf J Oncolog; 2019 May; 1(30):22-28. PubMed ID: 31242978
[TBL] [Abstract][Full Text] [Related]
11. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan dose schedule for the treatment of Ewing sarcoma.
Slotkin EK; Meyers PA
Pediatr Blood Cancer; 2023 Jan; 70(1):e30005. PubMed ID: 36184748
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
Wagner LM; McAllister N; Goldsby RE; Rausen AR; McNall-Knapp RY; McCarville MB; Albritton K
Pediatr Blood Cancer; 2007 Feb; 48(2):132-9. PubMed ID: 16317751
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma.
Dogan I; Iribas A; Ahmed MA; Basaran M
J Chemother; 2023 Jul; 35(4):343-347. PubMed ID: 35894948
[TBL] [Abstract][Full Text] [Related]
15. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.
Raciborska A; Bilska K; Drabko K; Chaber R; Pogorzala M; Wyrobek E; Polczyńska K; Rogowska E; Rodriguez-Galindo C; Wozniak W
Pediatr Blood Cancer; 2013 Oct; 60(10):1621-5. PubMed ID: 23776128
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy in patients with refractory Ewing sarcoma].
Raciborska A; Bilska K; Drabko K; Rogowska E; Chaber R; Pogorzała M; Wyrobek E; Połczyńska K; Rodriguez-Galindo C; Woźniak W
Med Wieku Rozwoj; 2013; 17(2):117-25. PubMed ID: 23988368
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.
Federico SM; Pappo AS; Sahr N; Sykes A; Campagne O; Stewart CF; Clay MR; Bahrami A; McCarville MB; Kaste SC; Santana VM; Helmig S; Gartrell J; Shelat A; Brennan RC; Hawkins D; Godwin K; Bishop MW; Furman WL; Stewart E
Eur J Cancer; 2020 Sep; 137():204-213. PubMed ID: 32795876
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection.
Pan HY; Morani A; Wang WL; Hess KR; Paulino AC; Ludwig JA; Lin PP; Daw NC; Mahajan A
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):349-57. PubMed ID: 25772182
[TBL] [Abstract][Full Text] [Related]
19. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]